FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020347377> ?p ?o ?g. }

• W2020347377 endingPage "477" @default.
• W2020347377 startingPage "474" @default.
• W2020347377 abstract "Optic neuritis occurred in three of our patients receiving treatment with alpha interferon-2b (Intron-A; 3MU thrice weekly) for chronic hepatitis. The complication appeared within, 1, 9 1/2 and 10 months of treatment, respectively. In all cases, blurred vision was the initial complaint and subsequent electrophysiologic investigation confirmed the presence of optic tract neuropathy. The patients had no other neurologic signs. Computerized tomography and magnetic resonance image of the brain were not remarkable. Psychiatric symptoms, in the form of an interferon-associated depressive reaction, were present in two of them; in one case, it was severe enough to require immediate discontinuation of treatment. In two patients the visual symptoms resolved and the parameters of neurophysiologic testing returned to normal within 1 month after stopping interferon. In one case, however, residual optic tract impairment associated with a unilateral central scotoma and a substantial decrease of visual acuity was present 2 years later, despite a course of methylprednizolone. In this patient the interferon treatment was continued for 3 months despite the visual symptoms, and he later received two additional interferon courses because of relapses of hepatitis. We conclude that clinically evident optic tract neuropathy may complicate interferon administration. Candidates for interferon treatment may need routine examination of optic fields and visual evoked potentials, before and during administration of the drug to avoid possibly permanent visual sequelae. Optic neuritis occurred in three of our patients receiving treatment with alpha interferon-2b (Intron-A; 3MU thrice weekly) for chronic hepatitis. The complication appeared within, 1, 9 1/2 and 10 months of treatment, respectively. In all cases, blurred vision was the initial complaint and subsequent electrophysiologic investigation confirmed the presence of optic tract neuropathy. The patients had no other neurologic signs. Computerized tomography and magnetic resonance image of the brain were not remarkable. Psychiatric symptoms, in the form of an interferon-associated depressive reaction, were present in two of them; in one case, it was severe enough to require immediate discontinuation of treatment. In two patients the visual symptoms resolved and the parameters of neurophysiologic testing returned to normal within 1 month after stopping interferon. In one case, however, residual optic tract impairment associated with a unilateral central scotoma and a substantial decrease of visual acuity was present 2 years later, despite a course of methylprednizolone. In this patient the interferon treatment was continued for 3 months despite the visual symptoms, and he later received two additional interferon courses because of relapses of hepatitis. We conclude that clinically evident optic tract neuropathy may complicate interferon administration. Candidates for interferon treatment may need routine examination of optic fields and visual evoked potentials, before and during administration of the drug to avoid possibly permanent visual sequelae." @default.
• W2020347377 created "2016-06-24" @default.
• W2020347377 creator A5039304659 @default.
• W2020347377 creator A5046139233 @default.
• W2020347377 creator A5049183697 @default.
• W2020347377 creator A5062998195 @default.
• W2020347377 date "1994-01-01" @default.
• W2020347377 modified "2023-09-27" @default.
• W2020347377 title "Optic tract neuropathy complicating low-dose interferon treatment" @default.
• W2020347377 cites W1979187226 @default.
• W2020347377 cites W2018732717 @default.
• W2020347377 cites W2062223349 @default.
• W2020347377 cites W2064702825 @default.
• W2020347377 cites W2093896551 @default.
• W2020347377 doi "https://doi.org/10.1016/s0168-8278(05)80331-9" @default.
• W2020347377 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7836721" @default.
• W2020347377 hasPublicationYear "1994" @default.
• W2020347377 type Work @default.
• W2020347377 sameAs 2020347377 @default.
• W2020347377 citedByCount "40" @default.
• W2020347377 countsByYear W20203473772012 @default.
• W2020347377 countsByYear W20203473772013 @default.
• W2020347377 countsByYear W20203473772016 @default.
• W2020347377 countsByYear W20203473772017 @default.
• W2020347377 countsByYear W20203473772019 @default.
• W2020347377 crossrefType "journal-article" @default.
• W2020347377 hasAuthorship W2020347377A5039304659 @default.
• W2020347377 hasAuthorship W2020347377A5046139233 @default.
• W2020347377 hasAuthorship W2020347377A5049183697 @default.
• W2020347377 hasAuthorship W2020347377A5062998195 @default.
• W2020347377 hasConcept C118487528 @default.
• W2020347377 hasConcept C141071460 @default.
• W2020347377 hasConcept C203014093 @default.
• W2020347377 hasConcept C2776178377 @default.
• W2020347377 hasConcept C2776572573 @default.
• W2020347377 hasConcept C2778233873 @default.
• W2020347377 hasConcept C2778715236 @default.
• W2020347377 hasConcept C2780640218 @default.
• W2020347377 hasConcept C2780837183 @default.
• W2020347377 hasConcept C2909179924 @default.
• W2020347377 hasConcept C71924100 @default.
• W2020347377 hasConcept C81182388 @default.
• W2020347377 hasConceptScore W2020347377C118487528 @default.
• W2020347377 hasConceptScore W2020347377C141071460 @default.
• W2020347377 hasConceptScore W2020347377C203014093 @default.
• W2020347377 hasConceptScore W2020347377C2776178377 @default.
• W2020347377 hasConceptScore W2020347377C2776572573 @default.
• W2020347377 hasConceptScore W2020347377C2778233873 @default.
• W2020347377 hasConceptScore W2020347377C2778715236 @default.
• W2020347377 hasConceptScore W2020347377C2780640218 @default.
• W2020347377 hasConceptScore W2020347377C2780837183 @default.
• W2020347377 hasConceptScore W2020347377C2909179924 @default.
• W2020347377 hasConceptScore W2020347377C71924100 @default.
• W2020347377 hasConceptScore W2020347377C81182388 @default.
• W2020347377 hasIssue "3" @default.
• W2020347377 hasLocation W20203473771 @default.
• W2020347377 hasLocation W20203473772 @default.
• W2020347377 hasOpenAccess W2020347377 @default.
• W2020347377 hasPrimaryLocation W20203473771 @default.
• W2020347377 hasRelatedWork W152087906 @default.
• W2020347377 hasRelatedWork W1964832404 @default.
• W2020347377 hasRelatedWork W2060137852 @default.
• W2020347377 hasRelatedWork W2135446701 @default.
• W2020347377 hasRelatedWork W2323551348 @default.
• W2020347377 hasRelatedWork W2777127156 @default.
• W2020347377 hasRelatedWork W2894765496 @default.
• W2020347377 hasRelatedWork W3203007193 @default.
• W2020347377 hasRelatedWork W4293802119 @default.
• W2020347377 hasRelatedWork W2063054490 @default.
• W2020347377 hasVolume "21" @default.
• W2020347377 isParatext "false" @default.
• W2020347377 isRetracted "false" @default.
• W2020347377 magId "2020347377" @default.
• W2020347377 workType "article" @default.